:quality(80)/s3.amazonaws.com/arc-authors/morningstar/adf521c2-d9af-477d-a6bc-03ec7ca34c40.jpg)
Zimmer Biomet Adjusts to New Leadership, and Wide Moat Remains Intact
Zimmer Biomet is the undisputed king of large joint reconstruction, and we expect aging baby boomers and improving technology suitable for younger patients to fuel solid demand for large-joint replacement that should offset price declines. However, Zimmer stumbled into a series of pitfalls in 2016-17, including integration issues, supply and inventory challenges, and quality concerns. The firm's efforts to turn around the firm have been admirable, though the pandemic slowed down progress. Now the firm is seeking to capitalize on the normalization of procedure volume and placements of its Rosa robot.